No products in the cart.
NKX3.1 is a protein encoded by the NKX3-1 gene and has been found to be positive in the vast majority of primary prostatic adenocarcinomas. A study has shown the sensitivity for identifying metastatic prostatic adenocarcinomas was 98.6% (68/69 cases positive) for NKX3.1 and 94.2% (65/69 cases positive) for prostate specific antigen (PSA). The specificity of NKX3.1 was 99.7% in various cancers and stains nuclei in both normal and prostate cancer. NKX3.1 antibody, used in combination with ERG monoclonal antibody [9FY], may represent a superior combination to aid in identifying tumors of prostatic origin.
Human NKX3.1 protein
Normal prostate or prostate cancer
1. Bowen C, Gelmann EP. NKX3.1 activates cellular response to DNA damage. Cancer Res. 2010 Apr 15; 70(8):3089-97.
2. Gurel B, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010 Aug; 34(8):1097-105.
3. Chuang AY, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007 Aug; 31(8):1246-55.
4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
5. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova, PA 1991; 7(9). Order code M29-P.